Sign In
Buy SRRK
$44.64
-0.0400 (-0.0895%)
At Close: Jun 03, 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SM
Why Scholar Rock Stock Bounced Higher on Monday
04:54pm, Monday, 15'th Sep 2025
Monday was a good day to be invested in Scholar Rock (SRRK 6.31%) stock. The clinical-stage biotech received a nod from an analyst initiating coverage on its shares, a move that sent its price more t
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:15pm, Friday, 12'th Sep 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for children and adults
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:15pm, Friday, 15'th Aug 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for children and adults
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for children and adults with spinal muscula
Scholar Rock Holding Corporation (SRRK) Q2 2025 Earnings Call Transcript
11:33pm, Wednesday, 06'th Aug 2025
Scholar Rock Holding Corporation (NASDAQ:SRRK ) Q2 2025 Earnings Conference Call August 6, 2025 8:00 AM ET Company Participants Akshay K. Vaishnaw - President of R&D, Member of Scientific Advisory Boa
Why Scholar Rock Stock Wilted on Wednesday
05:10pm, Wednesday, 06'th Aug 2025
It didn't take a high-powered academic to figure out why Scholar Rock's (SRRK -5.99%) share price swooned by more than 5% on Wednesday. That morning, the biotech published a quarterly earnings report
Scholar Rock (SRRK) Q2 Loss Widens 63%
04:54pm, Wednesday, 06'th Aug 2025
Scholar Rock (SRRK -6.39%), a late-stage biopharmaceutical company specializing in therapies for serious neuromuscular and rare diseases, released its second quarter 2025 earnings on August 6, 2025. T
Scholar Rock Reports Second Quarter 2025 Financial Results and Highlights Business Progress
07:00am, Wednesday, 06'th Aug 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--August 6, 2025-- Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal m
Director Sells 11,136 Shares of SRRK, a Stock Up 330% in Past Year
04:22pm, Wednesday, 23'rd Jul 2025
On July 18, 2025, Director Jeffrey S. Flier disclosed the sale of 11,136 shares of Scholar Rock (SRRK -0.68%) in an open market transaction.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular atrophy (
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:15pm, Friday, 18'th Jul 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal
Scholar Rock CEO on its drug that could preserve muscle in weight-loss drug users
06:25pm, Tuesday, 24'th Jun 2025
David Hallal, Scholar Rock CEO, joins 'Fast Money' to talk its recent drug study results that found its drug taken in combination with Zepbound helped prevent muscle loss.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular atrophy (
Why Scholar Rock Shares Are Soaring Today
01:41pm, Wednesday, 18'th Jun 2025
Shares of Scholar Rock Holding (SRRK 14.93%) are soaring today, up 13.7% as of 1:14 p.m. ET. The move comes as the S&P 500 and Nasdaq Composite were up modestly.
